

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistical parameters

When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).

n/a | Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
- Clearly defined error bars
State explicitly what error bars represent (e.g. SD, SE, CI)

Our web collection on [statistics for biologists](#) may be useful.

Software and code

Policy information about [availability of computer code](#)

Data collection

Fiji(ImageJ); Matlab version 2016b; Matlab version of Spot-On (v1.0; GitLab tag 92cdf210) (<https://gitlab.com/tjian-darzacq-lab/spot-on-matlab>)

Data analysis

Fiji(ImageJ); Matlab version 2016b; Matlab version of Spot-On (v1.0; GitLab tag 92cdf210) (<https://gitlab.com/tjian-darzacq-lab/spot-on-matlab>)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Uncropped scans for all western blots are provided in Supplementary Figure 1. The raw slowSPT and spaSPT data are freely available in Spot-On readable CSV and

Field-specific reporting

Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| | |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sample size | The number of trajectories used for SPT analysis was described in Fig. 2, and found to give statistically reliable findings. No sample size determination needed for rest. |
| Data exclusions | No data exclusions occurred in this study. |
| Replication | All experimental findings have been reliably reproduced at least three times and sometimes even more (e.g. SPT data). Any use of statistical methods have been described in relevant figure legends. |
| Randomization | This study does not involve randomization of samples/organisms/participants. |
| Blinding | This study does not require investigators to be blinded to group allocation during data collection and/or analysis. |

Reporting for specific materials, systems and methods

Materials & experimental systems

| n/a | Involvement in the study |
|-------------------------------------|-----------------------------------------------------------|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Unique biological materials |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Antibodies |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Human research participants |

Methods

| n/a | Involvement in the study |
|-------------------------------------|-------------------------------------------------|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

Antibodies

Antibodies used

AFF1: Bethylaboratories, Cat. #A302-344A, validated by WB, 1:1000 dilution
AFF4: Abcam, Cat. # ab57077, validated by WB, 1:1000 dilution
ELL2: Bethyl Laboratories, 238 Cat. # A302-505A, validated by WB, 1:1000 dilution
MePCE: Bethyl Laboratories, Cat. # A304-184A, validated by WB, 1:1000 dilution
RNA Pol II phospho-Ser2(3E10): Millipore, Cat. # 04-1571, validated by WB, 1:1000 dilution
RNA Pol II phospho-Ser5(3E8): Millipore, Cat. # 04-1572, validated by WB, 1:1000 dilution
Total RNA Pol II: Santa Cruz, Cat. # sc-56767, validated by WB, 1:1000 dilution
CDK7: Sigma, Cat. # C7089-.2ML, validated by WB, 1:3000 dilution
GST: CST, Cat. #2622, validated by WB, 1:1000 dilution
Tubulin: EMD CHEMICALS, Cat. #CP06, validated by WB, 1:2000 dilution
CycT1: Santa Cruz, Cat. # sc-10750, validated by WB (1:1000 dilution) and IF (1:200 dilution)
Anti-Flag: Sigma, Cat. # F3165, validated by WB and IF, 1:500 dilution
CDK9, LARP7, HEXIM1 and Brd4 abs: Homemade, validated by WB, 1:1000 dilution

Validation

All commercial antibodies were also validated by the manufactures as indicated on their web sites.

Eukaryotic cell lines

Policy information about [cell lines](#)

| | |
|----------------------------------------------------------------------|-------------------------------------------------------------------|
| Cell line source(s) | ATCC |
| Authentication | UC Berkeley Cell Culture Facility |
| Mycoplasma contamination | No contamination as verified by UC Berkeley Cell Culture Facility |
| Commonly misidentified lines (See ICLAC register) | N/A |